Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer Inc. (NYSE:PFE) reported in its fiscal Q1 2025 results that the first phase of its manufacturing optimization program ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.